Project Grant R21CA290500
Award Date
4/1/25
Completion Date
3/31/27
Dollars Obligated
$233K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $630,506 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Johns Hopkins University to develop therapeutic HPV vaccines that are highly effective against cervical cancers associated with diverse HPV16 variants. The primary goals are to: 1) characterize immune evasion by HPV16 variant epitopes, 2) evaluate growth and tumor microenvironment of spontaneous HPV-driven cervical carcinoma models, and 3) assess the efficacy of a novel HPV DNA...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $1,288,122 to New York University (NYU) from June 1, 2024 to May 31, 2029. The project aims to identify modifiable multi-level factors associated with HPV vaccine uptake in Kenya and Malawi. Key activities include:
Collecting primary qualitative and quantitative data, as well as analyzing secondary quantitative data, on factors affecting HPV vaccine uptake at the...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) will provide $191,700 to Northwestern University to develop and test a culturally-relevant digital health intervention targeting HPV vaccination among the U.S. Vietnamese population. The study, titled "HPV Education & Resources for the U.S. Vietnamese Population (HERO)," will leverage the Multiphase Optimization Strategy (MOST) framework to assess the feasibility, acceptability,...
The National Cancer Institute (NCI) awarded a $1,224,998 Cooperative Agreement (CFDA 93.393 Cancer Cause and Prevention Research) to New York University to implement the KUPEWA project. The project aims to identify optimal implementation strategies for increasing clinician recommendation of HPV vaccination for adolescent girls and young women living with HIV in Malawi. Key activities include refining an evidence-based set of implementable strategies, conducting an intervention optimization...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research program) provides funding to Ampedrna Biosciences LLC to develop a highly immunogenic mini-circular RNA (mRNA) vaccine for human papillomavirus (HPV)-related cancers. The award, totaling $398,823, supports research to demonstrate the superior efficacy of a multivalent mRNA HPV16 E6/E7 vaccine compared to a benchmark mRNA vaccine. Key objectives include showing that the mRNA vaccine can...
The National Cancer Institute (NCI) awarded a Cooperative Agreement of $705,051 to the University of Washington on May 15, 2024 under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program. The purpose of this award is to adapt and evaluate two programs to integrate human papillomavirus (HPV) self-sampling into federally qualified health centers (FQHCs) in order to increase cervical cancer screening rates in priority populations.
The project will conduct a two-phase...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower federal grant program (CFDA 93.398), supports research to investigate the role of ERBB2 signaling in human papillomavirus (HPV)-induced pathologies. The $148,280 award to Childrens Hospital Medical Center in Cincinnati, Ohio will be used to spatially resolve ERBB2 expression, activation, and downstream signaling in 3D organotypic epithelial rafts, and define the viral gene responsible for...
The University of North Carolina at Chapel Hill received a $157,744 Project Grant award from the Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) federal grant program. The purpose of this 4-year award is to develop and pilot an intervention to increase HPV vaccination rates among rural adolescents in North Carolina. Key activities include: 1) collaborating with rural clinics to assess the appropriateness and...
This $1,266,296 project grant awarded by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) will support research to model the impact of minor vaccine consent (VC) laws on COVID-19 vaccine uptake and transmission among adolescents.
The University of Pittsburgh, the primary awardee, will develop a comprehensive legal dataset of state and local VC laws, collaborate with community partners to...
This federal Project Grant award, totaling $2,466,139.00 and funded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research), aims to evaluate the effectiveness of the HPV vaccine in immunocompromised populations, including people with HIV, autoimmune conditions, and a history of solid organ or hematopoietic stem cell transplantation.
The research study will be conducted by Kaiser Foundation Hospitals' Kaiser Foundation Research...